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Background: The worldwide increase of diabetes, a long duration, slow progression disease, impacts health care
costs. The aim of this study was to estimate, from the society’s perspective, the annual cost per patient with Type 2
Diabetes (T2DM) at a specialized, outpatient center in the city of São Paulo, capital of São Paulo state, Brazil.
Methods: Data from 209 patients were collected during the years 2009 and 2010 in a São Paulo diabetes care center
which is part of the tertiary sector of SUS, Brazil’s National Health Care System. Data were collected by means of
interviews and reviews of medical charts, and the quality of life was appraised using the SF36-v2 questionnaire. Direct
medical costs were divided in five categories: 1) medication; 2) laboratory tests; 3) hospitalizations and procedures; 4)
reactive strips for capillary blood glucose monitoring; and 5) medical consultations. Direct non-medical costs referred to
transportation of patient and companion for treatment. Indirect costs included early retirements, sick leave and
absenteeism in the workplace. Statistical analysis of the data was performed by the SPSS software, version 17.0.
Results: Our sample comprised 122 women (58%) and 87 men (42%), with mean age of 63 years and average diabetes
duration of 13 years. The mean annual cost was US$ 1,844 per patient, out of which US$ 1,012 corresponded to direct
costs (55%) and US$ 831 to indirect costs (45%). From the direct medical costs, medications accounted for the greatest
proportion (42%), followed by reactive strips (27%), hospitalizations and procedures (14%), laboratory tests and image
examinations (7%), as well as medical consultations (4%). Non-medical costs (transportation) corresponded to 7% of
the total direct costs. Besides, the results indicated that men have better quality of life than women.
Conclusion: This study demonstrated a high T2DM cost in Brazil, considering the governmental per capita expenses in
health care, which accounted for US$ 466 in 2010 (World Health Statistics 2013 96-104 2013). Taking into account the
high prevalence of the disease (IDF Diabetes Atlas. 5th edition. 29-48 2012), this survey recommends the enforcement
of policies for the prevention of diabetes and its complications, and urges for better allocation of healthcare resources.
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The prevalence of diabetes is increasing worldwide [1-3].
The International Diabetes Federation (IDF) estimates
that 382 million people lived with diabetes in 2013 [4].
This figure represents a significant percentage of chronic
diseases around the globe [5,6], and according to IDF
projections this number will rise to 592 million people
in the planet in 2035 [6]. Most of these patients (more
than 90%) have Type 2 diabetes (T2DM), a nosological* Correspondence: natalie_borges@hotmail.com
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unless otherwise stated.entity that may be prevented [7,8]. T2DM is characterized
by long duration, slow progression and premature mortal-
ity from all causes, particularly coronary heart disease [9].
Patients with diabetes use the health care system more
frequently and for a longer period than those without this
condition [10]. Besides, diabetics have reduced productiv-
ity due to the disease or its complications, which impacts
not only the National Health Care System, but also the
patients’ quality of life [10,11]. Almost two thirds of that
population live in developing countries such as India,
China and Brazil, where an increase in the number of
diabetic patients in the next two decades [12-15] is foreseenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Brazil has the highest number of people with T2DM. The
prevalence of the disease in the adult population from the
age of 30 to 69 was estimated in 7.6% by a survey conducted
in the end of the 1980’s [16]. More recently, local studies
have indicated a 12.1% prevalence in the city of Ribeirão
Preto [17] and 13.5% in the city of São Carlos, in the inland
of São Paulo state [18], both percentages showing a clear
tendency of increase.
Considering the high prevalence of T2DM in Brazil, the
number of studies on the cost of this disease is insufficient
for an adequate evaluation of the real healthcare needs of
that population. Furthermore, this kind of survey consti-
tutes an important tool for better managing the financial
resources destined to SUS, which is decentralized and hi-
erarchized – Brazil’s National Health Care System (SUS) is
composed of basic health care units, laboratories and hos-
pitals, and aims at providing comprehensive health care to
all citizens.
The purpose of this work was to estimate the T2DM
annual costs in a specialized diabetes center in the city
of São Paulo, Brazil, from the society’s perspective.
Methods
The study was performed at a university’s outpatient
healthcare center which is part of the tertiary level of SUS.
For T2DM patients to integrate the study, inclusion cri-
teria were to be over 18 years old and to have regular
follow-ups at the outpatient healthcare center for at least
one year. The study comprised 209 patients, who were
consecutively selected on the basis of consultation sched-
ules from June 2009 to March 2010. All of them were
interviewed with the aid of three questionnaires – two of
them were filled out by the patient and the other one, by
the interviewer. Later, all data were verified by reviewing
the patient’s chart.
The first questionnaire was applied to all patients and was
divided into three parts. Part one covered demographic,
socioeconomic, educational data and productivity in the last
12 months of patients and caregivers; part two referred to
clinical data and to the use of healthcare resources along the
previous 12 months, such as medical consultations, tests,
procedures and hospitalizations, in addition to medications;
finally, part three resembled part two, but its data derived
from the patient’s chart. Parts two and three were compared,
and in case of discrepancies, the data in the patient’s chart
prevailed.
The second questionnaire, the Work Limitations Ques-
tionnaire (WQL), was applied to all employed patients in the
survey [19], in order to assess loss of productivity. The third
questionnaire, applied to all participants, was the SF-36v2
Health Survey [20], a generic instrument that has been used
all over the world to evaluate quality of life. Already trans-
lated to Portuguese and validated in Brazil [21], where thisstudy was conducted, the questionnaire shows several scales,
with scores varying from 0 (minimum) to 100 (maximum).
The amount of strips for blood capillary glucose self-
measurement (SBMG) was estimated based on the scheme
of insulin application. The costs of procedures, hospitaliza-
tions, consultations, strips and tests/examinations were cal-
culated based on SUS Unified Table of Procedures (SIGTAP)
[22], a comprehensive list of prices practiced by the National
Health Care System. As for the price of medications, this
study considered the weighted average of the unit value paid
by the government at public auctions, as recorded on the
price healthcare data bank of the Ministry of Health [23].
Medications considered in our study comprise four groups:
antidiabetic, antidislipidemic, antihypertensive and others
(diuretic, antiplatelet and drugs for cardiac insufficiency). It
was consider the number of tablets taken and the insulin
daily dose for the calculation of medication prices.
Indirect costs were calculated by adding the following: a)
the results from the WQL questionnaire of the surveyed
patients (annual loss rate multiplied by average salary); b)
the reported loss of housewives due to diabetes and its
complications (estimated as US$ 4.76 per hour multiplied
by the additional time required to perform the same tasks);
c) the loss due to early retirement, which was assessed
considering the last full salary earned when the patient was
employed, multiplied by twelve months; and d) loss related
to caregivers (workdays lost multiplied by the average
family salary). The exchange rate adopted in this study was
US$ 1 =R$ 1.837, which was the average exchange rate
reported by Brazil’s Central Bank from March 10th, 2009 to
April 9th, 2010. The total cost was calculated by adding the
direct costs (subdivided into medical and non-medical costs)
and the indirect costs.
The statistical analysis was performed using t-Student
or ANOVA test for all variables with normal distribution
standards. The Wilcoxon or the Kruskal-Wallis test was
adopted for the other ones, and the Spearman test was
used, with a 5% significance level, in order to verify corre-
lations among the variables.
Patients’ confidentiality was assured. This project was
approved by the decision No. 0553/09, taken by the
Research Ethics Committee of São Paulo Federal University –
UNIFESP.
Results and discussion
More than half of the sample was composed of women
(58%), and the average age of the population was 63 years
old. As for schooling, most patients (41.1%) had attended
but not finished primary school, while 25.4% had just par-
tially attended or finished middle school, a percentage which
reduced to 16.7% in the case of high school and to 12.4%
when it came to university. Just 4.3% of the sample had no
schooling at all. Regarding labor status, almost half of the
population was retired (47%), having average monthly
Borges et al. Diabetology & Metabolic Syndrome 2014, 6:122 Page 3 of 10
http://www.dmsjournal.com/content/6/1/122earnings of US$ 576.26 (US$ 19.21 per day). The mean dur-
ation of diabetes was 13 years, and 77% of the sample,
showed one or more chronic diabetes complications: 34%
had retinopathy; 46%, neuropathy; 40%, nephropathy; and
39%, macroangiopathy. Such complications were distrib-
uted as follows: 23% of the population did not have any
complications from diabetes; 28.2% developed just one;
23% had two; 17.7% had three, and 8.1% had four. The
glycated hemoglobin average (HbA1c) at the time of the
study reached 8.1%. Since we obtained the exact same value
considering the past 5 years and we lacked HbA1c data
from some patients at the time of the study, we chose to
use the 5-year-long average to increase the number of
patients considered. The mean body mass index (BMI) was
29.7 kg/m2. Regarding cardiovascular risks, 87% of the sam-
ple had arterial hypertension (HAS) and 78% dyslipidemia
(DLP). Just 8.6% were regular smokers. These characteris-
tics seem to be related to the T2DM population attending
the tertiary level of SUS; similar results were also yielded inTable 1 Demographic and clinical characteristics of the 209 s
Variable Male
Age (years) 64.35
N (%) 87 (41.6)
Education
Illiterate 2
Elementary school 50
Middle school 15
High school 20
University 14
Duration of T2DM (years) 12.6
HbA1c (%) of 5 years 7.81
BMI (kg/m2) 28.95
Complications of DM
Retinopathy 31
Neuropathy 48
Nephropathy 35
Macroangiopathy 43
Number of complications of DM
0 15
1 24
2 22
3 15
4 11
Risk factors
Arterial hypertension 76
Dyslipidemia 66
Smoking 7another study that characterized the T2DM population of
SUS [24]. Demographic data are gathered on Table 1.
According to the guidelines by the Brazilian Diabetes
Association (SBD) [25] and the American Diabetes Asso-
ciation (ADA) [26], a well-controlled diabetic patient must
have a HbA1c <7% and, being under this condition, he/she
should perform at least 2 HbA1c tests a year. In case of
having HbA1c >7% or if medication is changed, it is rec-
ommended the same test be performed 4 times along the
year. In our study, the average HbA1c was 8.1% (75.5% of
the studied population had an average HbA1c >7%), which
means that for most of the sample the disease was not well
controlled. Furthermore, 18.7% of the population did not
get the annual HbA1c test and 37.3% underwent just one
test a year (Table 2). This situation may be attributed not
only to the patients’ own conduct, but also to the over-
loaded health care system, which may be sometimes incap-
able of complying with the demand. Performing tests less
frequently than recommended may generate a reduction intudied patients
Female Total mean (%) SD
62.35 63.34 9.98
122 (58.4) –– ––
7 9 (4.3) 0,502
36 86 (41.1) 0,455
38 53 (25.4) 0,496
15 35 (16.7) 0,441
12 26 (12.4) 0,508
13.5 13.19 7.73
8.37 8.14 1.60
30.13 29.65 6.53
40 71 (34.0) 0.499
49 97 (46.4) 0.502
49 84 (40.2) 0.495
39 82 (39.2) 0.502
33 48 (23.0) 0,468
35 59 (28.2) 0,495
26 48 (23.0) 0,504
22 37 (17.7) 0,498
6 17 (8.1) 0,493
106 182 (87.1) 0.49
97 163 (78.0) 0.49
11 18 (8.61) 0.50
Table 2 Annual utilization of resources by the 209 analyzed patients
N* Mean** Std. deviation N*** male (SD) N*** female (SD)
Consultations
DM Consultations 209 2.23 1.469 205 (2.09) 261 (0.74)
Urology 30 2.17 1.147 45 (0.99) 20(1.40)
Cardiology 67 3.27 3.899 114 (2.50) 110 (4.86)
Dialysis 1 52.00 ——— —— 156
Endocrinology 9 3.00 2.000 6 (1.41) 21 (1.89)
Neurology 10 2.20 1.549 9 (1.41) 14 (1.30)
Ophthalmology 31 2.81 2.135 38 (1.32) 49 (2.62)
Nutrition 32 1.41 0.665 21 (0.73) 24 (2.62)
APA 6 3.50 6.124 1 20 (6.00)
Center – DM consultation 37 3.35 2.850 18 (0.43) 61 (2.09)
Podology 4 2.50 1.291 2 8 (1.25)
Imaging examinations
FO 4 0.66 0.568 66 (0.33) 82 (0.29)
Laser therapy 2 0.17 0.660 14 (1.07) 27 (1.16)
ECG 92 1.03 1.362 55 (1.84) 43 (0.66)
Echocardiogram 25 0.96 0.351 13 (0.28) 15 (0.32)
Ultrasound 45 1.04 0.424 19 (0.23) 34 (0.51)
Doppler ultrasound 10 1.10 0.315 4 (0.00) 7 (0.37)
Scintillography 6 0.50 0.548 2 (0.00) 2 (0.49)
Ergometric test 23 0.91 0.288 14 (0.00) 10 (0.37)
Laboratory exams 139 1.86 1.666 130 (2.12) 132 (1.13)
Creatine kinase
Creatinine 177 2.73 5.741 287 (8.26) 200 (1.75)
Glycaemia 174 1.93 1.089 164 (1.35) 193 (0.97)
Postprandial glycaemia 11 0.91 0.302 5 (0.00) 6 (0.35)
HbA1c 174 1.78 0.879 142 (0.95) 175 (0.82)
Total and frac. cholesterol 185 1.88 0.962 156 (0.97) 201 (0.99)
Alanine 139 1.86 1.666 165 (2.48) 145 (0.92)
Aspartate 177 2.73 5.741 165 (2.48) 144 (0.93)
Potassium 174 1.93 1.089 259 (8.82) 180 (1.77)
Sodium 11 0.91 0.302 246 (8.91) 151 (1.84)
Urea 174 1.78 0.879 246 (8.89) 153 (1.70)
Complete hemogram 185 1.88 0.962 200 (9.30) 106 (1.79)
Partial hemogram 22 1.05 0.213 13 (0.00) 13 (0.28)
Uric acid 34 1.24 0.819 28 (0.97) 16 (0.44)
TSH 121 1.53 0.886 79 (0.96) 109 (0.82)
Free T4 51 1.24 0.737 25 (0.98) 39 (0.52)
Gamaglutiltransf. 46 1.96 2.756 62 (3.35) 29 (1.24)
Alkaline phosphatase 30 2.20 3.316 44 (4.07) 22 (1.54)
Total Ca 46 1.76 2.141 46 (2.95) 35 (0.80)
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Table 2 Annual utilization of resources by the 209 analyzed patients (Continued)
Ionized Ca 18 3.44 7.838 52 (9.10) 10 (1.97)
Microalbuminuria 102 1.25 0.535 51 (0.62) 82 (0.47)
Triglycerides 24 1.04 0.359 10 (0.30) 15 (0.36)
Phosphorus 29 2.17 5.372 44 (7.95) 19 (0.47)
*Number of patients who utilized the resource.
**Number of times that the resource was used per patient, per year.
***Total number of exams or procedures or appointments.
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increases the risks of hospitalizations and complications,
which have a higher impact on direct costs.
The quality of life assessment (SF-36v2) showed a lower
score in the physical (PCS = 45.22) than in the mental do-
main (MCS = 47.51), being better for men (p-value = 0.0046
in the PCS domain and 0.0034 in the MCS). This had
already been observed on a Lithuanian study [27] – as
opposed to that survey, however, we found no statistically
significant difference in the quality of life due to schooling
or family income. Other studies have provided divergent
results. The research by Edelman et al. [28], for instance,
establishes that diabetes, at its initial stage, does not affect
the quality of life. The study by Poljičanin et al. [29] empha-
sizes, nevertheless, the negative influence of diabetes on the
quality of life, pinpointing that patients with diabetes and
hypertension show a lower score in both domains of the
SF-36 questionnaire, whereas in our study a statistically
significant difference was observed only in the physical
domain. On the other hand, the study by Venkataraman
et al. demonstrates that the quality of life of diabetic pa-
tients is mainly affected by a number of complications and
not by diabetes itself [30]. In our work, the presence of
neuropathy was related to a lower value in the physical do-
main (PCS), in accordance to the outcome of other studies
[30,31]. A review of the various tools to appraise the quality
of life of patients with diabetes confirms that the SF-36 ques-
tionnaire is appropriate for this population. However, some
researchers recommend the use of specific instruments since
they have observed that the SF-36 alone was unable to
quantify quality of life modifications despite clear clinical
improvements [32]. The results are shown on Table 3.
This study included 22 cases of hospitalizations from 21
patients, with average hospital stays of 9 days. Most hospi-
talizations (45%) related to macroangiopathy, while others
resulted from diabetes or nephric problems, amputations
and abscesses. Statistical comparisons between the groups
of hospitalized and non-hospitalized patients revealed no
significant difference regarding variables such as sex, age,
the time it takes to diagnose diabetes, HAS, DLP, HbA1c,
school attendance and social class, retinopathy, nephropa-
thy and neuropathy. Macroangiopathy, however, was cor-
related to a 2.96 higher probability of hospitalization.
The costs of hospitalizations and procedures in this study
(US$ 137 per patient/year) amounted to 14% of the directcosts, being slightly lower than those in the Mexican investi-
gation (18%) [33] – the Colombian and the ESCUDI studies
did not present this item separately. Previous researches on
the cost of illnesses (COI) showed that hospitalizations due
to diabetes and its complications are the main item of direct
costs – reaching, for instance, 43% in the work Economic
costs of diabetes in the U.S. in 2012 [2] (study based on the
prevalence of disease). A similar result was found by the
CODE-2 European research [34,35]. Performed with
approximately 7,000 patients in eight European cities, it
estimated the annual cost of T2DM at € 2,834 (US$
3,202) per patient, of which 55% corresponded to hos-
pitalizations and just 7% to antidiabetic medications.
However, it is worth noticing that not only the research
methodology, but also the health care system and the
socioeconomic scenario of the European study are com-
pletely different from the Brazilian case, so the results of
both works allow for no straightforward comparisons.
Regarding the utilization of resources in our study, the
annual average of consultations per patient, according to
each specialty, was 3 consultations with a diabetologist,
1 with a cardiologist, 0.3 with a nephrologist, 0.1 with a
neurologist, 0.4 with an ophthalmologist and 0.2 with a
nutritionist. Detailed results are available on Table 2.
The average annual cost of T2DM was US$ 1,844 per
patient, out of which US$ 1,012 (55%) per patient cor-
responded to direct costs, subdivided into medical costs
(US$ 940) and non-medical costs (US$ 72). Expenses
with medications (US$ 422 per patient/year) had the highest
impact on direct costs (42%). Those medications were di-
vided in four categories: antidiabetics (US$ 113), hypocho-
lesterolinemics (US$ 253), antihypertensives (US$ 25)
and others (US$ 31). Among the drugs for glycemic control,
NPH insulin was most widely used (87% of the patients),
closely followed by metformin (73%). We observed that
42.6% of the patients bought their medication at regular
drugstores, either because the health care centers were out
of stock, or because drugstores offered more “modern”
drugs. However, for the purposes of this study, the costs
of medications were calculated as if all the patients had got
them from health care centers. In spite of the differences in
socioeconomic environment and research methodology,
studies performed in Brazil [36], Colombia [37] and Iran
[38] also point out medications as the main item in the
direct costs of diabetes (Table 4). In the ESCUDI Brazilian
Table 3 Average values of PCS and MCS (the two main variables in the SF-36v2 questionnaire), according to gender,
social class, HbA1c level, hospitalization and complications
Domain Variable Média Std. deviation P-value
PCS
Sex
All 45.22 9.82
0.0046Female 43.65 10.14
Male 47.43 8.95
HAS
No 49.41 8.06
0.0 173Yes 44.65 9.92
DLP
No 47.16 7.79
0.2267Yes 44.74 10.28
Retinopathy
No 46.03 9.75
0.0900Yes 43.71 9.84
Nephropathy
No 45.94 9.60
0.2242Yes 44.21 10.09
Neuropathy
No 46.80 9.33
0.0 160Yes 43.43 10.10
Macroangiopathy
No 45.61 9.84
0.4232Yes 44.45 9.85
Hospitalization
No 46.11 9.51
0.0002Yes 37.34 9.20
HbA1c
1 (4%-6%) 43.90 10.47
0.0345
2 (6.1%-6.5%) 43.72 12.79
3 (6.6%-7.5%) 47.60 9.33
4 (7.6%-8.5%) 41.92 9.98
5 (>8.5%) 46.03 8.95
IBGE* categories
1 (>20 MW) 44.71 12.06
0.9547
2 (10-20 MW) 46.99 8.45
3 (4-10 MW) 45.49 9.33
4 (2-4 MW) 45.25 10.25
5 (<2 MW) 44.16 9.27
MCS
Sex
All 47.51 13.31
0.0034Female 45.11 14.10
Male 50.83 11.42
HAS
No 46.53 9.90
0.3 155Yes 47.65 13.73
DLP
No 47.02 12.44
0.5584Yes 47.64 13.61
Retinopathy
No 47.16 13.09
0.5614Yes 48.18 13.80
Nephropathy
No 47.10 12.81
0.3792Yes 48.10 14.07
Neuropathy
No 48.30 12.69
0.4516Yes 46.62 14.00
Macroangiopathy
No 47.04 13.10
0.3279Yes 48.64 13.22
Internment No 48.41 12.81 0.0 107
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Table 3 Average values of PCS and MCS (the two main variables in the SF-36v2 questionnaire), according to gender,
social class, HbA1c level, hospitalization and complications (Continued)
Yes 39.42 15.33
HbA1c
1 (4%-6%) 48.44 13.79
0.0964
2 (6.1%-6.5%) 49.82 11.28
3 (6.6%-7.5%) 50.66 12.08
4 (7.6%-8.5%) 48.23 13.63
5 (>8.5%) 44.31 13.92
IBGE categories*
1 (>20 MW) 51.89 8.46
0.3877
2 (10-20 MW) 50.44 9.94
3 (4-10 MW) 49.71 13.06
4 (2-4 MW) 46.66 12.15
5 (<2 MW) 45.47 14.09
*Categories defined by the Brazilian Institute of Geography and Statistics (IBGE) according to family income. The average minimum wage (MW) during the period
was approximately US$ 263 per month.
The statistically significant variations of the PCS and MCS averages (p-value ≤0,05) are highlighted below.
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Type 2 diabetes in SUS, medications represented 48% of
the direct costs, a result that is similar not only to our
findings (42%), but also to those of the Colombian (47%)
and of the Iranian (46%) studies, although the percentage
of the latter referred only to the patients who had no
complications.
In our study, the annual cost of reactive strips for capil-
lary blood glucose monitoring was US$ 269 per patient
(27% of the direct costs), higher than hospitalizations and
procedures (US$ 137 per patient; 14% of direct cost),
when in fact the opposite should be expected. These
findings can be explained, however, by the low amount
of hospitalizations (22), considering the number of indivi-
duals who use reactive strips (123), usually more than once aTable 4 Results comparison to other T2DM COI studies
Cost-of-illness study
of T2DM Colombia
Cost-of-illness
study of T2DMIran
Rosib
Ange
M
Year of
publication
2009 2011
Total cost* 2.7 billion 3.78 billion 4.5
Total annual cost 847 1707 3
per patient*
Indirect cost 66% 51%
Direct cost 34% 49%
Medication 47% 46%***
Laboratory –– ––
Procedures and –– ––
Hospitalizations
Consultations
–– ––
*The costs in all studies are shown in US$, except where indicated.
**Indirect costs were not calculated in these studies.
***This percentage refers only to patients without complications.
****This percentage refers to the cost of laboratory exams (7%) added to those of sday. The result also corroborates data of the Brazilian study
on T1DM [39]. It shows that health care technology has the
greatest impact on the treatment expenses of T1DM, which
has a similar treatment to T2DM at its most advanced stage.
The total annual cost of laboratory tests was US$ 71
per patient (7% of the total direct costs) and that of
medical consultations was US$ 42 per patient (4%).
In this research, the total annual cost of T2DM was
US$ 1,844 per patient, lower than the US$ 2,810 calcu-
lated in ESCUDI for patients using SUS’ tertiary sector.
Such discrepancy might result from methodological differ-
ences, such as the fact that this study did not compute
medications for obesity and psychiatric problems, which
are responsible for an annual increase in direct costs of
approximately US$ 293 per patient in ESCUDI.el de los
les T2DM
exico
CODE-2 B.
Jonsson T2DM
Europe
Luciana R.
Bahia T2DM
Brazil
Natalie B.
Borges T2DM
Brazil
2010 2002 2011
billion EUR 29 billion –– ––
194** EUR 2108 1844
2834**
–– –– 33% 45%
–– –– 63% 55%
–– 7% 48% 42%
–– 21% –– 34%****
18% 55% –– 14%
–– 18% –– 4%
trips (27%).
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paring the various studies on the cost of the disease and the
impossibility to generalize the results, due to differences in
aspects such as diabetes demography and epidemiology,
clinical practices, distribution and availability of health-
care resources, among other factors [40]. The lack of
standardization also hinders comparisons with a large num-
ber of studies on the cost of diabetes performed in devel-
oped countries, considering that the estimates significantly
vary depending upon the methodological approach, the
variables taken into account and the health care system in
each country [38].
Non-medical expenses (transportation) amounted to US$
72 per patient per year (7% of the total direct cost), corre-
sponding to an annual average of 11 rides to and from the
health care center per patient. We observed that half of the
sampled individuals (52%) live in the southern district of
the city, where the treatment unit is located, 17% dwell in
the eastern district, 5% in the western, 4% in the northern,
1% reside downtown and 11% did not give any address
information. The rest of the patients (8%) live in other
cities, hence they have higher transportation expenses for
each visit. The productivity loss of the workers (n = 31)
was 3%, corresponding to US$ 109,460.48 per year. The
unemployed patients due to diabetes or its complications
and those who reported early retirement and absenteeism
in the workplace caused by diabetes and its complications
(n = 30) had an annual loss of US$ 48,649.10, while the loss
of housewives (n = 14) amounted to US$ 12,162.28 and that
of the caregivers (n = 3) to US$ 3,474.94. By adding these
numbers we obtained an annual indirect cost of US$
173,746.80, which gives an average individual cost of US$
831 per patient per year, representing 45% of the total
annual cost. These data are shown on Table 5.
This research has some limitations, such as being carried
out just at one diabetes care center. Although the facility isTable 5 Detailed costs of the study
Annual costs per
patient (US$)
Total cost 1,844
Indirect costs (subtotal) 831
Direct costs (subtotal) 1012
Medical costs*
Medical appointments 42
Exams 71
Strips 269
Hospitalization and procedures (all patients) 137
Medications** 422
Non-medical costs
Transport 72
*Costs were calculated using the bottom-up approach with the SUS price as a refer
**Costs were calculated based on [20] Banco de Preços em Saúde [Data Bank on Helocated at an important capital city (São Paulo), the results
might not reflect the situation throughout the country;
possible distortions in our results are nonetheless hard to
assess, given the lack of information on key aspects such
as regional distribution of patients, access to health care
centers and severity of the disease. Since the selection of
patients was not ideal, some bias may be noticed, includ-
ing the predominance of retired people in the sample and
the low number of patients having dialysis. The direct
costs might also be underestimated since the government
has been keeping the prices of the National Health Care
System frozen for many years. Hence, the results from this
research might not reflect the actual average individual
annual cost of T2DM patients at outpatient health care
centers all over the country.
In addition to that, the indirect costs might have been
underestimated, for some damages caused by diabetes were
not considered: there are intangible costs that cannot be
measured, such as pain, suffering and an overall decrease
in levels of quality of life. According to this study, patients
with diabetic neuropathy and arterial hypertension have a
statistically significant reduction of quality of life in the
physical aspect, while hospitalized patients and women
showed lower levels in both domains.
The few existing works on the cost of diabetes in Brazil
provide a valuable overview of the matter. However, more
studies are needed for better understanding the healthcare
needs of this growing population and adequately distributing
healthcare resources, which represented 9% of the Gross
Domestic Product (GDP) in 2010, and the cost of T2DM
found in this study, correspond to 15.7% of the Per capita
GDP of 2012, according to the World Health Organization
(WHO) [41]. The percentage of the healthcare resources is
comparable with that of developed countries such as
Australia (9.0%), Finland (9.0), Ireland (9.2), Japan (9.2),
Norway (9.3%), Sweden (9.6%) and the United KingdomTotal annual
costs (US$) % of the direct costs % of the total costs
385,300 –– 100
173,747 –– 45
211,553 100 55
8,688 + 202 4
28,615 + 1,991 14
88,182 + 472 42
14,949 + 152 7
ence.
althcare Prices].
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http://www.dmsjournal.com/content/6/1/122(9.6%). Nevertheless, in Brazil, most resources come from
private institutions, which provide treatment to a significantly
reduced number of patients when compared to the National
Health Care System (SUS). In 2010, the government dis-
bursed only 47% of the total amount allocated in the health
care sector, while in the aforementioned countries that per-
centage was significantly higher: 68.5% in Australia, 74.5% in
Finland, 69.2% in Ireland, 80.3% in Japan, 85.5% in Norway,
81.0% in Sweden and 83.2% in the United Kingdom.
The relationship between the GDP and the population of
each country, i. e., the gross domestic product per capita,
must also be taken into account for that analysis. While in
Brazil the per capita annual government expenditure on
health at average exchange rate was only US$ 466, it
reached US$ 3,545 in Australia, US$ 2,947 in Finland, US$
2,933 in Ireland, US$ 3,179 in Japan, US$ 6,875 in Norway,
US$ 3,816 in Sweden and US$ 2,908 in the United
Kingdom.
Conclusion
The growing incidence and prevalence of diabetes con-
firmed by epidemiologic studies all over the world (IDF)
[36] increases the number of people using the health care
system of each country. Most of those systems – including
SUS in Brazil – are unable to cope with such increase in
demand, hence it is essential to enforce policies for the
prevention of diabetes and its complications and to better
allocate healthcare resources.
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